Biotech Values

[vinmantoo]

I disagree
but to be clear enta didn't state if the data is stat sig or not (i presume if you combine the 2 drug arms to placebo to up the N that it is stat sig but again I don' think it matters)

Exactly. The improvement of Covid symptoms was dose dependent and statistically significant, which clearly demonstrated that EDP-235 has potent anti-viral activity and has a very good chance for success in a phase 3 trial, especially if it includes some high risk group patients. The new data provided evidence for anti-viral activity and buttresses ENTA's views the rapid viral clearing in nasal swabs in the placebo group was due to previous infections in the treatment group, It wasn't needed in my view as the FDA doesn't care about viral titer in nasal swabs as that isn't a metric for approval. The FDA only cares about symptom improvement and lessening of severe disease, hospitalization and or death. Still, it is welcome news anyway to see a dose dependent effect of EDP-235 on viral levels.